At the 30th European Hematology Association (EHA) Congress, hematology experts highlight breakthroughs in treatment, the importance of patient voices, and challenges in making innovations accessible worldwide.
Marina Kremyanskaya, MD, PhD
Advertisement
Marina Kremyanskaya, MD, PhD, is an associate professor of medicine at the Icahn School of Medicine at Mount Sinai.
Articles by Marina Kremyanskaya, MD, PhD
Early results from the phase 1 SANRECO trial suggest that divesiran is safe and well tolerated, and may reduce the need for phlebotomy in patients with polycythemia vera by increasing hepcidin levels and improving iron regulation, according to lead investigator Marina Kremyanskaya, MD, PhD.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Enfortumab Vedotin Plus Pembro Cuts Risk of Disease Progression, Death 60% for Patients With MIBC Who Can’t Have Chemo With Bladder Removal
2
Abemaciclib Plus Endocrine Therapy Improves Overall Survival in High-Risk Early Breast Cancer
3
New Biomarkers, Drug Targets Identified for Colorectal Cancer
4
Colorblind Devices, Longer-Wavelength Lasers Offer Safer Options for Darker Skin Tones: Ariella Kauvar, MD
5
